3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts

FomoAnxiety · 2026-03-23T17:25:26+00:00

Top Wall Street analysts recommend three biotech stocks as Strong Buys: Coya Therapeutics, Solid Biosciences, and CytomX Therapeutics, all with significant upside potential according to recent ratings.

FomoAnxiety

2026-03-23 17:25:26

Abstract generation in progress

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new Buy rating recently and has a significant upside as well.

Claim 30% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

To find more stocks like these, take a look at TipRanks’ Analyst Top Stocks tool. It shows you a real-time list of all stocks that have been recently rated by Top-ranking Analysts.

Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.

**Coya Therapeutics COYA +0.95% ▲ **– Coya Therapeutics is a biotech company developing therapies to reduce inflammation in neurodegenerative diseases. Today, H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on the stock with a price target of $18 per share. In the last three months, all three Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 280%.

**Solid Biosciences SLDB +4.41% ▲ **– Solid Biosciences is a biotech company developing gene therapies for Duchenne muscular dystrophy and other neuromuscular diseases. Today, Wedbush analyst Laura Chico maintained a Buy rating on the stock with a price target of $17 per share. In the last three months, all nine Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 154.4%.

**CytomX Therapeutics CTMX +1.80% ▲ **– CytomX Therapeutics is a biotech company developing targeted cancer therapies using its Probody platform. Today, Piper Sandler analyst Edward Tenthoff maintained a Buy rating on the stock and increased the price target to $12 from $10 per share. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 202.23%.

Who Are the Top Analysts?

TipRanks ranks financial analysts according to the success rates of their ratings and the average return on each of their ratings. The Top Analysts have each earned a five-star ranking, thanks to the accuracy and profitability of their ratings over time.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.